Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
26.79
+2.33 (9.53%)
At close: Jul 30, 2026, 4:00 PM EDT
28.75
+1.96 (7.32%)
After-hours: Jul 30, 2026, 5:07 PM EDT
Castle Biosciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 62.12 | 116.73 | 119.71 | 98.84 | 122.95 | 329.63 |
Short-Term Investments | 204.69 | 182.78 | 173.42 | 144.26 | 135.68 | - |
Cash & Short-Term Investments | 266.81 | 299.51 | 293.13 | 243.1 | 258.63 | 329.63 |
Cash Growth | -3.31% | 2.17% | 20.58% | -6.00% | -21.54% | -19.57% |
Accounts Receivable | 48.34 | 43.38 | 51.22 | 38.3 | 23.48 | 17.28 |
Inventory | 10.58 | 10.25 | 8.14 | 7.94 | 3.98 | 2.02 |
Other Current Assets | 15.37 | 7.96 | 7.67 | 6.29 | 6.21 | 4.81 |
Total Current Assets | 341.1 | 361.1 | 360.15 | 295.64 | 292.29 | 353.74 |
Net Property, Plant & Equipment | 118.88 | 112.24 | 62.71 | 37.74 | 26.5 | 16.88 |
Goodwill | 95.1 | 99.57 | 106.23 | 117.34 | 126.35 | 88.92 |
Other Long-Term Assets | 6.1 | 5.65 | 2.15 | 2.63 | 2.2 | 3.02 |
Total Assets | 561.18 | 578.56 | 531.24 | 453.34 | 447.33 | 462.57 |
Accounts Payable | 9.67 | 18.71 | 6.9 | 10.27 | 4.73 | 2.55 |
Accrued Expenses | 41.01 | 47.22 | 40.55 | 36.26 | 29.62 | 21.16 |
Current Portion of Long-Term Debt | 2.92 | 0.42 | 0.28 | - | - | - |
Current Portion of Leases | 1.42 | 1.33 | 1.67 | 1.14 | 1.78 | 1.18 |
Other Current Liabilities | 1.5 | 1 | - | - | - | - |
Total Current Liabilities | 56.51 | 68.68 | 49.39 | 47.67 | 36.13 | 24.89 |
Long-Term Debt | 7.16 | 9.64 | 9.75 | - | - | - |
Long-Term Leases | 25.16 | 25.53 | 14.66 | 14.2 | 11.53 | 6.9 |
Other Long-Term Liabilities | 2.32 | 3.84 | 1.61 | 0.21 | 0.52 | 19.05 |
Total Long-Term Liabilities | 34.64 | 39.01 | 26.01 | 14.4 | 12.05 | 25.95 |
Total Liabilities | 91.15 | 107.68 | 75.4 | 62.07 | 48.18 | 50.83 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Additional Paid-in Capital | 711.12 | 694.86 | 655.7 | 609.48 | 560.41 | 505.48 |
Accumulated Other Comprehensive Income | -0.26 | 0.27 | 0.23 | 0.14 | -0.38 | - |
Retained Earnings | -240.87 | -224.28 | -200.13 | -218.37 | -160.91 | -93.77 |
Shareholders' Equity | 470.03 | 470.87 | 455.84 | 391.27 | 399.15 | 411.74 |
Total Liabilities & Equity | 561.18 | 578.56 | 531.24 | 453.34 | 447.33 | 462.57 |
Total Debt | 36.65 | 36.91 | 26.34 | 15.34 | 13.31 | 8.08 |
Net Cash (Debt) | 230.16 | 262.59 | 266.79 | 227.76 | 245.32 | 321.55 |
Net Cash Growth | -3.53% | -1.57% | 17.13% | -7.15% | -23.71% | -20.95% |
Net Cash Per Share | 7.76 | 9.06 | 9.12 | 8.50 | 9.42 | 12.79 |
Book Value | 470.03 | 470.87 | 455.84 | 391.27 | 399.15 | 411.74 |
Book Value Per Share | 15.84 | 16.24 | 15.58 | 14.60 | 15.32 | 16.38 |
Tangible Book Value | 374.93 | 371.3 | 349.61 | 273.93 | 272.8 | 322.82 |
Tangible Book Value Per Share | 12.64 | 12.81 | 11.95 | 10.22 | 10.47 | 12.84 |